Vizimpro

Active Ingredient(s): Dacomitinib
FDA Approved: * September 27, 2018
Pharm Company: * PFIZER INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Vizimpro Overview

Dacomitinib (PF-00299804) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[1] Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals.[2][3][4] Additional Phase III trials are ongoing.[2] In 201...

Read more Vizimpro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dacomitinib

Recent Vizimpro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dacomitinib
  • Tablet: 15mg, 30mg, 45mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vizimpro: (4 results)

Sorted by National Drug Code
  • 0069-0197 Vizimpro 15 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
  • 0069-1198 Vizimpro 30 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
  • 0069-2299 Vizimpro 45 mg Oral Tablet, Film Coated by Pfizer Laboratories Div Pfizer Inc
  • 63539-197 Vizimpro 15 mg Oral Tablet, Film Coated by U.S. Pharmaceuticals

Other drugs which contain Dacomitinib or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA